Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: a new indication for propranolol treatment
until further notice
SourceJournal of Pediatric Hematology/Oncology, 33, 4, (2011), pp. e171-3
Article / Letter to editor
Display more detailsDisplay less details
Paediatrics - OUD tm 2017
Journal of Pediatric Hematology/Oncology
SubjectIGMD 1: Functional imaging; N4i 1: Pathogenesis and modulation of inflammation; ONCOL 4: Quality of Care; NCEBP 14: Cardiovascular diseases ONCOL 5: Aetiology, screening and detection
Kaposiform hemangioendothelioma is a rare vascular tumor in children. Especially, in association with the Kasabach-Merritt Phenomenon it can be life threatening. The management of these patients is very difficult and an aggressive treatment regime is required. Several multimodality and chemotherapeutic regimens have been described but with variable success and many side effects. We present a 6-week-old boy with Kaposiform hemangioendothelioma and Kasabach-Merritt Phenomenon. Ongoing propranolol treatment with only 4 initial courses of vincristine resulted in a remission that lasted at least 1 year.
Upload full text
Use your RU credentials (u/z-number and password) tolog in with SURFconextto upload a file for processing by the repository team.